Skip to main content
Article
A phase I dose escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) in combination with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in advanced solid tumors.
Journal of Clinical Oncology (2014)
  • Neil Howard Segal, Memorial Sloan Kettering Cancer Center
  • F. Stephen Hodi, Harvard University
  • Rachel E. Sanborn, Providence Portland Medical Center
  • Thomas Gajewski, University of Chicago
  • Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center
  • Walter John Urba
  • Bernard A. Fox, Oregon Health & Science University
  • Suzanne Louise Topalian, Johns Hopkins University
  • Drew M. Pardoll, Johns Hopkins University School of Medicine
  • Georgia Kollia, Bristol-Myers Squibb
  • Dan McDonald, Bristol-Myers Squibb
  • Su Young Kim, Bristol-Myers Squibb
  • William Howard Sharfman, Johns Hopkins University
Publication Date
May 20, 2014
Citation Information
Neil Howard Segal, F. Stephen Hodi, Rachel E. Sanborn, Thomas Gajewski, et al.. "A phase I dose escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) in combination with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in advanced solid tumors." Journal of Clinical Oncology Vol. 32 (2014)
Available at: http://works.bepress.com/walter-urba/134/